{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single-arm&page=17",
    "query": {
      "intervention": "Single-arm",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 9926,
    "total_pages": 993,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single-arm&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single-arm&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-01T12:14:56.881Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07288359",
      "title": "Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced HR+/HER2- Breast Cancer",
        "Advanced CCNE1-amplified Solid Tumors",
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "GVV858",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 205,
      "start_date": "2025-12-29",
      "completion_date": "2031-05-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-29",
      "last_synced_at": "2026-11-01T12:14:56.881Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Nashville, Tennessee • San Antonio, Texas",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07288359"
    },
    {
      "nct_id": "NCT01165580",
      "title": "A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cytomegalovirus Infections, Heart Transplantation"
      ],
      "interventions": [
        {
          "name": "valganciclovir [Valcyte]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "124 Days",
        "sex": "ALL",
        "summary": "Up to 124 Days"
      },
      "enrollment_count": 17,
      "start_date": "2011-05",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-11-01T12:14:56.881Z",
      "location_count": 16,
      "location_summary": "Loma Linda, California • Palo Alto, California • Aurora, Colorado + 13 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01165580"
    },
    {
      "nct_id": "NCT03743246",
      "title": "A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Lymphoma, Non-Hodgkin"
      ],
      "interventions": [
        {
          "name": "JCAR017",
          "type": "DRUG"
        },
        {
          "name": "Lymphodepleting",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "Up to 25 Years"
      },
      "enrollment_count": 21,
      "start_date": "2018-10-17",
      "completion_date": "2024-01-26",
      "has_results": true,
      "last_update_posted_date": "2024-08-15",
      "last_synced_at": "2026-11-01T12:14:56.881Z",
      "location_count": 9,
      "location_summary": "Duarte, California • Redwood City, California • St. Petersburg, Florida + 6 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03743246"
    },
    {
      "nct_id": "NCT07719088",
      "title": "Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Aging",
        "Longevity",
        "Biomarkers of Aging"
      ],
      "interventions": [
        {
          "name": "Psilocybin (Usona Institute)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Charles Raison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "60 Years to 80 Years"
      },
      "enrollment_count": 50,
      "start_date": "2026-12",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-01T12:14:56.881Z",
      "location_count": 1,
      "location_summary": "Edwards, Colorado",
      "locations": [
        {
          "city": "Edwards",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07719088"
    },
    {
      "nct_id": "NCT04394624",
      "title": "Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "SAR408701",
          "type": "DRUG"
        },
        {
          "name": "ramucirumab",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2020-08-31",
      "completion_date": "2024-10-24",
      "has_results": true,
      "last_update_posted_date": "2025-06-06",
      "last_synced_at": "2026-11-01T12:14:56.881Z",
      "location_count": 3,
      "location_summary": "Detroit, Michigan • Buffalo, New York • Waco, Texas",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Waco",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04394624"
    },
    {
      "nct_id": "NCT06123988",
      "title": "Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Prolonged Overnight Fasting",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Moderate-Intensity Exercise",
          "type": "BEHAVIORAL"
        },
        {
          "name": "General Health Education Sessions",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 260,
      "start_date": "2024-09-09",
      "completion_date": "2029-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-11-01T12:14:56.881Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Miami, Florida • Boston, Massachusetts",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06123988"
    },
    {
      "nct_id": "NCT05756569",
      "title": "Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Squamous Cell Carcinoma",
        "Locally Advanced Bladder Carcinoma",
        "Malignant Renal Pelvis Neoplasm",
        "Malignant Ureter Neoplasm",
        "Malignant Urethral Neoplasm",
        "Metastatic Bladder Carcinoma",
        "Stage III Bladder Cancer AJCC v8",
        "Stage IV Bladder Cancer AJCC v8",
        "Unresectable Bladder Carcinoma",
        "Urachal Adenocarcinoma",
        "Bladder Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Enfortumab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2023-09-26",
      "completion_date": "2027-12-16",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-11-01T12:14:56.881Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05756569"
    },
    {
      "nct_id": "NCT07483320",
      "title": "Extracorporeal Shockwave Therapy and Platelet-Rich Plasma for Midportion Achilles Tendinopathy",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Achilles Injuries Tendon",
        "Achilles Tendinopathy (AT)",
        "Achilles Tendinitis, Left Leg",
        "Achilles Tendinitis, Right Leg",
        "Achilles Tendon Pain",
        "Achilles Tendonitis"
      ],
      "interventions": [
        {
          "name": "Platelet Rich Plasma",
          "type": "DEVICE"
        },
        {
          "name": "Extracorporeal Shockwave Therapy",
          "type": "DEVICE"
        },
        {
          "name": "Sham PRP",
          "type": "DEVICE"
        },
        {
          "name": "Sham ESWT",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Spaulding Rehabilitation Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 100,
      "start_date": "2026-10-15",
      "completion_date": "2028-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-11-01T12:14:56.881Z",
      "location_count": 1,
      "location_summary": "Cambridge, Massachusetts",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07483320"
    },
    {
      "nct_id": "NCT03904524",
      "title": "SET-to-Meet; Pilot Testing of a Nurse-led Intervention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Critical Illness"
      ],
      "interventions": [
        {
          "name": "SET-to-Meet",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 97,
      "start_date": "2019-06-13",
      "completion_date": "2023-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-05-08",
      "last_synced_at": "2026-11-01T12:14:56.881Z",
      "location_count": 2,
      "location_summary": "Greensburg, Pennsylvania • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Greensburg",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03904524"
    },
    {
      "nct_id": "NCT01655524",
      "title": "The Impact of the Routine Aminophylline Administration Following Regadenoson Stress on SPECT Myocardial Perfusion",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "ASSUAGE Protocol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2012-07",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2021-10-11",
      "last_synced_at": "2026-11-01T12:14:56.881Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01655524"
    }
  ]
}